Funding for this research was provided by:
Roche Diagnostica Brasil (PMR-HPV)
Text and Data Mining valid from 2020-04-28
Received: 18 December 2019
Accepted: 13 April 2020
First Online: 28 April 2020
Ethics approval and consent to participate
: In 2017, a law in the city of Indaiatuba that replaces conventional cytology by the DNA-HPV test for cervical cancer screening was approved. CCSP-HPV has become a standard of care. The UNICAMP Ethics Committee approved the study protocol (number 1,045,580, May 1, 2015) to evaluate the implementation and cost-effectiveness of CCSP-HPV. The Ethics Committee also approved the waiver of the Informed Consent Form, considering that this study will analyze data from health system records, without direct contact with patients.
: Not applicable.
: Roche Diagnostics reviewed the study protocol before deciding to participate and to provide financial support for some activities of this study, including its HPV test chosen for the screening program. The authors have no other competing interests to declare.